The Food Safety and Standards Authority of India (FSSAI) has officially suspended the manufacturing license of Dior Pharmaceuticals with immediate effect, following a comprehensive regulatory inspection that uncovered major and critical non-conformities at its nutraceutical manufacturing facility.
The regulatory audit revealed severe systemic failures across essential quality and safety protocols, constituting direct violations of core provisions under the Food Safety and Standards (FSS) Act, 2006. Inspectors documented that the facility was operating under severely deficient Good Manufacturing Practices (GMP), Good Hygiene Practices (GHP), and Food Safety Management Systems (FSMS).
The inspection highlighted major shortcomings across overall regulatory compliance, including facility infrastructure, sanitation, housekeeping, storage and handling practices, process controls, personnel hygiene, water quality monitoring, and recordkeeping. FSSAI emphasized that because nutraceutical products belong to a high-risk category intended for direct human consumption, operating without essential food safety controls poses a substantial risk to public health and compromises product safety, quality, and traceability.
Under strict enforcement orders, the Food Business Operator (FBO) has been directed to immediately halt all manufacturing and processing operations. The suspension will remain enforced until all identified non-conformities are thoroughly rectified, and complete compliance is established to the satisfaction of the Competent Authority.
Written by: Pragna Biswas
Graphics by: Pramit Hazra
